CL2022002786A1 - Formas cristalinas de compuestos orgánicos - Google Patents

Formas cristalinas de compuestos orgánicos

Info

Publication number
CL2022002786A1
CL2022002786A1 CL2022002786A CL2022002786A CL2022002786A1 CL 2022002786 A1 CL2022002786 A1 CL 2022002786A1 CL 2022002786 A CL2022002786 A CL 2022002786A CL 2022002786 A CL2022002786 A CL 2022002786A CL 2022002786 A1 CL2022002786 A1 CL 2022002786A1
Authority
CL
Chile
Prior art keywords
crystalline forms
organic compounds
compound
useful
treatment
Prior art date
Application number
CL2022002786A
Other languages
English (en)
Inventor
K Dilger Andrew
A Galella Michael
Smith Daniel
M Ziemba Theresa
Lüdeker David
Xiouras Christos
Ahuja Dipali
Angelina J Cleeren Dirk
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of CL2022002786A1 publication Critical patent/CL2022002786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen formas cristalinas del Compuesto (I). El Compuesto (I) es útil como agente anti-tromboembólico en el tratamiento de enfermedades cardiovasculares.
CL2022002786A 2020-04-10 2022-10-07 Formas cristalinas de compuestos orgánicos CL2022002786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063008161P 2020-04-10 2020-04-10

Publications (1)

Publication Number Publication Date
CL2022002786A1 true CL2022002786A1 (es) 2023-04-14

Family

ID=75690727

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002786A CL2022002786A1 (es) 2020-04-10 2022-10-07 Formas cristalinas de compuestos orgánicos

Country Status (14)

Country Link
US (1) US20230151010A1 (es)
EP (1) EP4132930A1 (es)
JP (1) JP2023521411A (es)
KR (1) KR20230008742A (es)
CN (1) CN115916780A (es)
AU (1) AU2021253946A1 (es)
BR (1) BR112022020243A2 (es)
CA (1) CA3179957A1 (es)
CL (1) CL2022002786A1 (es)
CO (1) CO2022016067A2 (es)
IL (1) IL297206A (es)
MX (1) MX2022012523A (es)
PE (1) PE20231071A1 (es)
WO (1) WO2021207659A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024030409A1 (en) 2022-08-01 2024-02-08 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Also Published As

Publication number Publication date
CO2022016067A2 (es) 2023-01-26
IL297206A (en) 2022-12-01
WO2021207659A1 (en) 2021-10-14
PE20231071A1 (es) 2023-07-17
KR20230008742A (ko) 2023-01-16
EP4132930A1 (en) 2023-02-15
JP2023521411A (ja) 2023-05-24
BR112022020243A2 (pt) 2022-11-22
CA3179957A1 (en) 2021-10-14
MX2022012523A (es) 2022-11-07
US20230151010A1 (en) 2023-05-18
AU2021253946A1 (en) 2022-12-15
CN115916780A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
CO2022002413A2 (es) Composiciones y métodos para tratar la psoriasis y la dermatitis atópica usando prevotella histicola
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
CL2020002696A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CR20140113A (es) Imidazopiridazinas sustituidas con amino
BR112021017620A2 (pt) Compostos macrocíclicos
UY38160A (es) Partículas implantables y métodos relacionados
PE20160200A1 (es) Inhibidores de bromodominios
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
PE20121032A1 (es) Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4] triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropanocarboxilico como inhibidor de jak
CU20150140A7 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituídas
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
UY37832A (es) Dihidrooxadiazinonas
CO2018001628A2 (es) Composiciones y formulaciones antimicrobianas
UY37971A (es) Derivados de indol macrocíclicos sustituidos
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
CO2022000481A2 (es) Inhibidores de enzimas
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
CL2022002786A1 (es) Formas cristalinas de compuestos orgánicos
CO2021005540A2 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano (thp)
ECSP20080995A (es) Derivados de tetrahidrotienopiridina n–sustituidos y sus usos
CL2023000061A1 (es) Macrociclos y su uso
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos